These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28762205)

  • 1. Next-generation AAV vectors for clinical use: an ever-accelerating race.
    Weinmann J; Grimm D
    Virus Genes; 2017 Oct; 53(5):707-713. PubMed ID: 28762205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.
    Grimm D; Büning H
    Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosters for adeno-associated virus (AAV) vector (r)evolution.
    Szumska J; Grimm D
    Cytotherapy; 2023 Mar; 25(3):254-260. PubMed ID: 35999132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.
    Grimm D; Zolotukhin S
    Mol Ther; 2015 Dec; 23(12):1819-31. PubMed ID: 26388463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants.
    Rapti K; Maiakovska O; Becker J; Szumska J; Zayas M; Bubeck F; Liu J; Gerstmann E; Krämer C; Wiedtke E; Grimm D
    J Vis Exp; 2022 Oct; (188):. PubMed ID: 36342179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.
    Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants.
    Weinmann J; Weis S; Sippel J; Tulalamba W; Remes A; El Andari J; Herrmann AK; Pham QH; Borowski C; Hille S; Schönberger T; Frey N; Lenter M; VandenDriessche T; Müller OJ; Chuah MK; Lamla T; Grimm D
    Nat Commun; 2020 Oct; 11(1):5432. PubMed ID: 33116134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors.
    El Andari J; Grimm D
    Biotechnol J; 2021 Jan; 16(1):e2000025. PubMed ID: 32975881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing.
    de Alencastro G; Pekrun K; Valdmanis P; Tiffany M; Xu J; Kay MA
    Hum Gene Ther; 2020 May; 31(9-10):553-564. PubMed ID: 32024384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation AAV vectors-do not judge a virus (only) by its cover.
    Domenger C; Grimm D
    Hum Mol Genet; 2019 Oct; 28(R1):R3-R14. PubMed ID: 31261383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.
    Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Robust and All-Inclusive Pipeline for Shuffling of Adeno-Associated Viruses.
    Herrmann AK; Bender C; Kienle E; Grosse S; El Andari J; Botta J; Schürmann N; Wiedtke E; Niopek D; Grimm D
    ACS Synth Biol; 2019 Jan; 8(1):194-206. PubMed ID: 30513195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Assembly-Activating Protein on Molecular Evolution of Synthetic Adeno-Associated Virus Capsids.
    Herrmann AK; Große S; Börner K; Krämer C; Wiedtke E; Gunkel M; Grimm D
    Hum Gene Ther; 2019 Jan; 30(1):21-35. PubMed ID: 29978729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
    Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
    Kwon I; Schaffer DV
    Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Throughput Dissection of AAV-Host Interactions: The Fast and the Curious.
    Herrmann AK; Grimm D
    J Mol Biol; 2018 Aug; 430(17):2626-2640. PubMed ID: 29782834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.
    Sen D
    J Biomed Sci; 2014 Nov; 21(1):103. PubMed ID: 25425174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.
    Lam AK; Frabutt D; Li L; Xiao W
    Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.